Program
Simvastatin
Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.
Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.
Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 290 open or running | phase 4since Sep 7, 2005 | Sep 21, 2004 | none ahead |
| Abbottits history only | 80 open or running | phase 3since Mar 25, 2004 | Mar 25, 2004 | none ahead |
| Eli Lillyits history only | 60 open or running | phase 2since Apr 15, 2010 | Apr 15, 2010 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Merckits history only | 60 open or running | phase 3since May 24, 2007 | May 24, 2007 | none ahead |
| Pfizerits history only | 40 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 21, 2010 | Jul 21, 2010 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Entero Therapeuticsits history only | 10 open or running | early phase 1since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Organon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Sep 21, 2004.
- Dec 8, 20062 phase 3 studies in HypercholesterolemiaNCT00409773, NCT00413972
- Jan 17, 2007Phase 4 study in HypercholesterolemiaNCT00423579 · 120 enrolled
- Feb 28, 2007Phase 4 study in HypercholesterolemiaNCT00442897 · 229 enrolled
- Apr 18, 2007Phase 3 study in HypercholesterolemiaNCT00462748 · 786 enrolled
- May 24, 2007Phase 3 study in HypercholesterolemiaNCT00479713 · 618 enrolled
- Jul 2, 2007Phase 3 study in HypercholesterolemiaNCT00496730 · 256 enrolled
- Oct 29, 2007Phase 3 study in Coronary DiseaseNCT00551447 · 616 enrolled
- Mar 31, 20084 phase 3 studiesNCT00652301, NCT00651560, NCT00651391 and 1 more
- Mar 31, 2008Phase 4 study in HypercholesterolemiaNCT00650663 · 247 enrolled
- Apr 1, 20082 phase 4 studies in HypercholesterolemiaNCT00653835, NCT00654628
- Apr 1, 2008Phase 3 study in HypercholesterolemiaNCT00653523 · 151 enrolled
- Aug 19, 2008Phase 4 study in Lupus Erythematosus, SystemicNCT00739050 · 4 enrolled
- Mar 12, 2009Phase 3 study in Cardiovascular DiseasesNCT00862251 · 808 enrolled
- Mar 6, 2019Phase 3 study in Hyperlipoproteinemia Type IINCT03884452 · 50 enrolled
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
All 29 Organon leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | May 24, 2001 | 50 |
| NCT00862251Cardiovascular Diseases | 3 | Completed | Mar 2011 | 808 |
| NCT00739050Lupus Erythematosus, Systemic | 4 | Terminated | Feb 1, 2008 | 4 |
| NCT00654628Hypercholesterolemia | 4 | Completed | Jul 1, 2009 | 173 |
| NCT00653835Hypercholesterolemia | 4 | Completed | Aug 1, 2004 | 153 |
| NCT00653523Hypercholesterolemia | 3 | Completed | Jun 1, 2009 | 151 |
| NCT00652301Cholesterol | 3 | Completed | Apr 2004 | 40 |
| NCT00651560Hyperlipidemias | 3 | Completed | Dec 23, 2005 | 167 |
| NCT00651391Hypercholesterolemia | 3 | Terminated | Sep 1, 2004 | 28 |
| NCT00650819Hypercholesterolemia | 3 | Completed | Feb 1, 2005 | 240 |
| NCT00650663Hypercholesterolemia | 4 | Completed | Sep 1, 2004 | 247 |
| NCT00551447Coronary Disease | 3 | Completed | Mar 2003 | 616 |
| NCT00496730Hypercholesterolemia | 3 | Completed | Aug 2008 | 256 |
| NCT00479713Hypercholesterolemia | 3 | Completed | Mar 1, 2008 | 618 |
| NCT00462748Hypercholesterolemia | 3 | Completed | Jun 2008 | 786 |
| NCT00442897Hypercholesterolemia | 4 | Completed | Oct 2008 | 229 |
| NCT00423579Hypercholesterolemia | 4 | Completed | Mar 1, 2008 | 120 |
| NCT00413972Hypercholesterolemia | 3 | Completed | Nov 2006 | 392 |
| NCT00409773Hypercholesterolemia | 3 | Completed | Jul 2008 | 1,143 |
| NCT00398294Hypercholesterolemia · Taiwan | 4 | Completed | Apr 4, 2006 | 30 |
| NCT00389896HDL Cholesterol | 3 | Completed | Oct 4, 2002 | 150 |
| NCT00271817Hypercholesterolemia | 3 | Completed | Feb 2008 | 1,220 |
| NCT00166530Atherosclerosis | 4 | Completed | Feb 2007 | 367 |
| NCT00166504Hypercholesterolemia | 4 | Completed | Oct 2007 | 203 |
| NCT00157924Hypercholesterolemia | 4 | Completed | Sep 2007 | 190 |
| NCT00129402Hypercholesterolemia | 3 | Completed | Jun 2007 | 248 |
| NCT00132717Hypercholesterolemia | 3 | Completed | Jun 1, 2007 | 450 |
| NCT00093899Hyperlipidemias | 3 | Completed | Sep 2005 | 611 |
| NCT00092157Hypercholesterolemia | 3 | Completed | Mar 3, 2003 | 571 |
How it is read
Names in the registry
- “Simvastatin”, 44 entries
- “simvastatin”, 14 entries
- “ezetimibe (+) simvastatin”, 9 entries
- “Fenofibrate/Simvastatin”, 5 entries
- “Ezetimibe + Simvastatin”, 4 entries
Codes read as this program: MK0733.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 35 studies
- Diabetes Mellitus, Type 2, 9 studies
- Hyperlipidemias, 7 studies
- Cardiovascular Diseases, 3 studies
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.